IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immatics N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$7.05+0.32 (+4.75%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | $30.27M | $-0.04 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 21, 2023 | Before market open | – | – | – |
Press releases
Announcements Immatics filed with the SEC
Immatics Announces $150 Million Underwritten Offering
EX-99.1 to Form 6-K
Unaudited Interim Condensed Consolidated Statement of Loss of Immatics N.V.
EX-99.1 to Form 6-K
Immatics Announces Second Quarter 2026
EX-99.2 to Form 6-K
ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V.
EX-99.1 to Form 6-K
OF the ANNUAL GENERAL MEETING OF
EX-99.1 to Form 6-K
GENERAL MEETING OF immatics N.V.
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific
EX-99.2 to Form 6-K
Immatics Presents Clinical Activity and Response
EX-99.3 to Form 6-K
Unaudited Interim Condensed Consolidated Statement of Loss of Immatics N.V.
EX-99.1 to Form 6-K
Immatics Announces First Quarter 2026
EX-99.2 to Form 6-K
Immatics Announces Four Upcoming Oral Presentations
EX-99.1 to Form 6-K
Cell Therapy Using Immatics’ TCR
EX-99.1 to Form 6-K
IMA203CD8 PRAME Cell Therapy Data
EX-99.1 to Form 6-K
Immatics Announces $125 Million Underwritten
EX-99.1 to Form 6-K
Unaudited Interim Condensed Consolidated Statement of Loss of Immatics N.V.
EX-99.1 to Form 6-K
Immatics Announces Third Quarter 2025
EX-99.2 to Form 6-K
Immatics Achieves Clinical Proof-of-Concept of
EX-99.1 to Form 6-K
Immatics Appoints Amie Krause as Chief People
EX-99.1 to Form 6-K
Immatics Highlights Compelling Anti-Tumor Activity
EX-99.1 to Form 6-K
Appoints Venkat Ramanan as Chief Financial Officer
EX-99.1 to Form 6-K
Unaudited Interim Condensed Consolidated Statement of Loss of Immatics N.V.
EX-99.1 to Form 6-K
Immatics Announces Second Quarter 2025 Financial Results
EX-99.2 to Form 6-K
Immatics Corporate Presentation August 13, 2025 Exhibit 99.3
EX-99.3 to Form 6-K
MINUTES OF THE ANNUAL GENERAL
EX-99.1 to Form 6-K
NOTICE OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V.
EX-99.1 to Form 6-K
OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V.
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Immatics IMA203 PRAME Cell Therapy Data Presented
EX-99.1 to Form 6-K